Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRD-4730 in Catecholaminergic Polymorphic Ventricular Tachycardia
NCT06658899Phase 2Recruiting
- Sponsor
- Cardurion Pharmaceuticals
- Start
- Dec 2025
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of CRD-4730 in catecholaminergic polymorphic ventricular tachycardia (CPVT) (3 arms), sponsored by Cardurion Pharmaceuticals. Primary endpoint: Primary Outcome Measures at Day 101. Started Dec 2025; status: recruiting.
02
Drugs
CRD-4730
03
Conditions
catecholaminergic polymorphic ventricular tachycardia (CPVT)
Beyond the preview
Go deeper on NCT06658899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06658899.